Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ligand Pharmaceuticals Incorporated - Common Stock
(NQ:
LGND
)
157.31
+2.06 (+1.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ligand Pharmaceuticals Incorporated - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Ligand (LGND) Q2 Revenue Jumps 15%
August 07, 2025
Via
The Motley Fool
Topics
Intellectual Property
Ligand Pharmaceuticals (NASDAQ:LGND) Surpasses Q2 2025 Earnings Estimates with Strong Royalty Growth
August 07, 2025
Ligand Pharmaceuticals (LGND) beat Q2 2025 earnings estimates with strong royalty growth, raising full-year guidance. Stock dipped slightly pre-market but gained 16.3% over the past month.
Via
Chartmill
Earnings Scheduled For August 7, 2025
August 07, 2025
Via
Benzinga
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
July 31, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts
July 10, 2025
The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.
Via
Stocktwits
Topics
Government
Earnings Scheduled For May 8, 2025
May 08, 2025
Via
Benzinga
Earnings Scheduled For February 27, 2025
February 27, 2025
Via
Benzinga
Demystifying Ligand Pharmaceuticals: Insights From 10 Analyst Reviews
December 11, 2024
Via
Benzinga
A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals
November 08, 2024
Via
Benzinga
Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease
July 10, 2025
Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks.
Via
Benzinga
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
July 09, 2025
Via
Benzinga
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings
April 17, 2025
Via
Benzinga
Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated
April 17, 2025
Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.
Via
Stocktwits
Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts
October 21, 2024
Via
Benzinga
The Latest Analyst Ratings For Ligand Pharmaceuticals
October 03, 2024
Via
Benzinga
Dow Falls Over 1%; US Initial Jobless Claims Decline
April 17, 2025
Via
Benzinga
Topics
Stocks
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity
April 17, 2025
Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.
Via
Benzinga
Analyst Sees Big Upside In Ligand's Capital-Efficient Biotech Strategy
April 10, 2025
Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth.
Via
Benzinga
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
April 10, 2025
Via
Benzinga
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
February 13, 2025
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 06, 2025
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
December 10, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
December 09, 2024
The companies held competing events on Sunday to discuss their multiple myeloma treatments.
Via
Investor's Business Daily
Ligand to Present at Stifel 2024 Healthcare Conference
November 14, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
November 07, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
November 01, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
October 23, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know
October 21, 2024
Via
Benzinga
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
October 17, 2024
Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment...
From
Palvella Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.